Update: 27/09/2011  12.05

MolMed's cancer pipeline in clinical development - September 2011
  
  

MolMed’s activities are primarily focused on development of novel therapeutics for tumours with very different patterns and very different levels of incidence, but sharing the common traits of severity and high need of new therapeutic options.
On one hand, MolMed is addressing tumours considered to be uncommon - although with ever-growing incidence because of exposure to environmental conditions that contribute to disease onset - that have no or very few therapeutic options available.

On the other hand, clinical trials of MolMed's investigational therapies address widespread indications with a much wider range of treatments available or in development, but with many patients becoming either intolerant (because reaching cumulative toxicity) or refractory (because of loss of disease control over time) to all possible treatment lines. For these heavily pre-treated patients with no efficacious treatment lines left, MolMed devotes its efforts to offer a new therapeutic option.

To succesfully address the cure of each of these tumours, MolMed is developing two dinstinct investigational therapies, both entirely new and giving origin to novel therapeutic classes, relying on two different technology platforms:

• TK , a cell therapy product for blood tumours:this approach is aimed at making available to all patients the curative potential of transplants of haematopoietic stem cells derived from the bone marrow of a healthy donor, that is currently feasible in a safe and effective way only if the donor is fully compatible with the patient, a condition that can be satisfied only for approximately 50% of candidates to the transplant;
  
  
• NGR-hTNF , a biological drug targeting tumour blood vessels: this approach is based on the use of a particular kind of drug, a selective vascular targeting agent whose molecular target is a structure which is only present on blood vessels that feed the tumour mass. The antivascular effect of the drug cuts off supplies of oxygen and nutrients to the tumour, thus blocking its growth.